Clinical Trial Goal
To find out:
- The highest dose of talabostat that’s safe to give
- If talabostat is safe and works well to treat AML or MDS that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have AML or MDS that has relapsed or is refractory
- Do not have acute promyelocytic leukemia
- Do not have untreated lymphoma in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Talabostat is a drug that blocks the protein DPP in certain cells.
You’ll get:
- Talabostat – A pill that you take by mouth 2 times each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 1 year. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved talabostat.
Contacts
Eric S Winer, MD, 1 617-632-2053, erics_winer@dfci.harvard.edu
Eric S Winter, MD, 1 617-632-2053, erics_winer@dfci.harvard.edu
Locations
Dana Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Eric s Winer, MD, 617-632-3000, EricS_Winer@DFCI.HARVARD.EDU
Sponsors
lead: Eric Stephen Winer, MD
